Abstract. Evidence has suggested that salidroside inhibits the proliferation and invasion of renal clear cell, lung, breast, and colon cancer. However, effect of salidroside on colorectal cancer (CRC) cells against oxaliplatin (L-OHP) resistance remains unclear. In the present study, the CRC HT-29 cell line and L-OHP resistance HT-29/L-OHP cell line were used to evaluate the effect, and mechanism of salidroside on L-OHP resistance. The results demonstrated that the activity of HT-29 cells was lower compared with that of HT-29/L-OHP cells following L-OHP intervention, and was accompanied with varied expression levels of drug resistant proteins. The combination of salidroside and L-OHP weakened cell activity significantly compared single utilization. Compared with the control group, salidroside intervention resulted in a higher percentage of HT-29/L-OHP cells in the G 0 /G 1 stage, and reduced percentage in the G 2 /M stage, but no significant variation in the S stage. The HT-29/L-OHP cells exhibited increased apoptosis rates and caspase-3 activity, but decreased metastatic, and invasive abilities following salidroside intervention. Quantitative polymerase chain reaction and western blot analysis detected variations in the expression levels of associated genes in HT-29/L-OHP cells following salidroside intervention. In all, the results of the present study revealed that salidroside is able to decrease the activity and invasive capacity of HT-29/L-OHP cells, and treatment with salidroside is associated with increased apoptosis of cancer cells through the regulation of certain genes.
Introduction
Colorectal cancer (CRC) has become a fatal threat with the 4th highest morbidity and 5th highest mortality in all cancers (1) , and incidence of CRC also increased dramatically in China (2, 3) . Due to difficulty of detecting this disease at early stage, the majority of patients were diagnosed as being at the progressive stage at the first visit to hospital. Although the chemotherapy, one of the main treatments for CRC, is being updated, the outcome remains unsatisfactory and results in poor prognosis (4) (5) (6) (7) (8) (9) (10) . Cancer cells can develop resistance to chemotherapeutic drugs, such as oxaliplatin (L-OHP), and this has been demonstrated as the crucial factor of chemotherapy failure (11) (12) (13) . Given this fact, reversing the drug resistance of cancer cells has been regarded as a practical method for enhancing chemotherapy efficacy and improving the prognosis of patients.
Salidroside is the active ingredient of Rhodiolae, a plant has been used in the Far East and Russia traditional medicine for a variety of diseases (14) (15) (16) . Evidence has demonstrated that salidroside can inhibit the proliferation and invasion of abnormal cells in renal clear cell cancer (17) , lung cancer (18) , breast cancer (19) , and colon cancer (20) . However, the effect of salidroside on CRC cells against L-OHP resistance remains unclear.
In present study, we assessed the effect of salidroside on the activity, cycle and apoptosis of L-OHP resistance CRC cells in vitro. We also detected the expression variation of drug-resistant genes before and after salidroside intervention, in terms of MRP-1, P-gp, LOXL2, Survivin, Livin, Bcl-2 and Bax, and also investigated the molecular mechanism and potential clinical value of salidroside.
Materials and methods
Cell lines and cell culture. CRC cell line HT-29 was obtained from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). L-OHP-resistant CRC line HT-29/L-OHP was cultivated and identified by our research team using increased concentration, which reached a resistant index (RI) of 4.26 for L-OHP. HT-29 and HT-29/L-OHP were cultivated under 5% CO 2 and 37˚C with Dulbecco's modified Eagle's medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), which contains 10% fetal calf serum (FCS). Trypsin (0.25%) (Gibco; Thermo Fisher Scientific, Inc.) with 0.02% EDTA was used for the digestive transfer. L-OHP (1.5 µg/ml) was added into the substrate of HT-29/L-OHP to maintain the drug-resistant phenotype until 2 weeks before the experiment.
Detection of cell activity with SRB assay. Single-cell suspension was prepared and adjusted to 10 6 /ml whereas salidroside (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and L-OHP (Laboratoires Thissen, Belgium) were added after the cell attachment. Cell fixation was conducted using 50% TCA (50 µl) under 4˚C for 1 h which was followed by elution (5 times) using ultrapure water and air drying. 100 µl sulphorhodamine B (SRB; Pierce, Rockford, IL, USA) were added to each well for 10 min in dark place (25˚C) and then discarded. The optical density (OD) value was detected using microplate reader under 545 nm. The cell activity was presented as the OD ratio which is defined as OD ratio in experimental group/OD ration in control groups. This experiment was repeated for 3 times.
Detection of the expressions of targeted proteins. After quantification (ABC assay), 60 µg proteins from specimens in each group was purified by polyacrylamide gel electrophoresis (PAGE) and then transferred to PVDF membrane for overnight (4˚C) after adding first antibody or β-actin (Sigma-Aldrich; Merck KGaA). Elution was performed using TBST for 3 times and then the second antibody marked by horseradish peroxidase (HRP) was added. After incubation under 25˚C for 1 h, chemiluminescence was applied for coloration following by stripe scanning.
Detection of cell cycle. After centrifugation, cells were fixed using 70% alcohol under 4˚C. The cell cycle was determined by flow cytometry (FCM; Becton-Dickinson, San Jose, CA, USA) with 100 µl cell suspension (1x10 6 /ml) which was pretreated by PBS (containing 50 µg/ml propidium iodide, 100 µg/ml RNase A and 0.2% Triton X-100) under 4˚C for 30 min in dark.
Detection of cell apoptosis. The cell apoptosis rate was detected by Annexin V-FITC/propidium iodide (PI) detection kit (Jiamei North Biological Technology Co., Ltd., Beijing, China) with 100 µl cell suspension (1x10 6 /ml) which was pretreated using 5 µl Annexin V-FITC and 10 µl PI under 25˚C for 15 min in dark.
Cell scratch assay. Single-cell suspension was adjusted to 5x10 4 /ml and then transferred to the 24-well plate for cultivating during a period of 48 h. After discarding DMEM, scratching was conducted using the 200 µl tips which was followed by 24-h culture using serum-free medium. Wound healing was inspected under microscope after washing out the scratched cells. The distance and ratio of cell migration were calculated.
Transwell chamber assay. The pore size of the polycarbonate membrane of the Transwell chamber is 8 µm where the upper chamber was membraned using 100 µl Matrigel under ultraviolet radiation for 2 h. Cells were inoculated to the 6-well plate for 1x10 6 /ml per well and intervened for 24 h when growing up to 60-70%. Single-cell suspension (200 µl) was inoculated to the upper chamber and then placed to the 24-well plate, while the lower chamber was cultivated using DMEM (containing 10% FCS). After 24 h culture, the Matrigel and cells in the upper chamber were removed using aseptic swab. The polycarbonate membrane was fixed using methanol for 10 min and then colored by crystal violet. Cell counts were calculated by inspecting 5 random fields under high magnification. The inhibition rate of invasion was defined as (1 -counts of invasive cells in experimental group/counts of invasive cells in control group) x 100%. The procedure was repeated for 3 times.
Real-time PCR assay. Total RNA of cells were extracted and retransformed into cDNA, which was then amplified by PCR for detecting the mRNA expressions of targeted molecules. The primers are shown in Table I . The amplified results were identified using agarose gel electrophoresis. The results of fluorogenic quantitative PCR was calculated using 2 -ΔΔCt method with β-actin working as internal reference.
Detection of caspase-3 activity. N-acetyl-Asp-Glu-Val-As p-7-amino-4-trifluorom ethylcoumarin (Ac-DEVD-AFC; Calbiochem, San Diego, CA, USA) was utilized to detect the activity of caspase-3, caspase-3 analysis buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA and 10 mM DTT) was added into 15 µl protein extracts. After incubation under 37˚C for 2 h, specimens were treated using 15 µl Ac-DEVD-AFC solution (2 mM) and then detected by ELIASA reader under 505 nm.
Statistical analysis. Mean ± SD was recorded to demonstrate the results of cell activity, western blot analysis, cell cycle, apoptosis, invasion/metastasis, values of fluorogenic quantitative PCR test and caspase-3 activity. The heterogeneities 
Results

The effect of L-OHP on HT-29 and HT-29/L-OHP cells.
To evaluate the effect of L-OHP on HT-29 and HT-29/L-OHP cells, different dosages of L-OHP were applied for intervention and the cell activity was detected by SRB assay. As shown in Fig. 1 , the activity of HT-29 was less obvious than HT-29/L-OHP after the intervention (P<0.05), suggesting a stronger resistance of HT-29/L-OHP against L-OHP, and 0.5 µg/ml L-OHP was selected for further studies. (Fig. 3B and C) , based on which the accurate dosage and treatment period (48 h) of salidroside were determined. The cell activity decreased further with the combined use of salidroside and L-OHP (Fig. 3D) . 
The expressions of drug-resistant proteins in HT-
The effect of salidroside on the invasion and migration of HT-29/L-OHP and HT-29 cells.
HT-29/L-OHP and HT-29 cells were pretreated by 80 µg/ml salidroside for 48 h respectively, and then detected with scratch test to evaluate the cell migration activity and Transwell chamber assay to assess the cell invasion capacity. As shown in Fig. 6 , the inhibition ratio and invasion descended in a dose-dependent manner after the intervention, indicating that salidroside could inhibit the invasion and migration of HT-29/L-OHP and HT-29 cells. 
The effect of salidroside on the expressions of drug-resistant genes and caspase-3 activity in HT-29/L-OHP and HT-
P<0
.05 vs. group 3 in (D). Group 1 (salidroside 10 µg/ml); group 2 (salidroside 10 µg/ml combined with L-OHP); group 3 (salidroside 80 µg/ml); and group 4 (salidroside 80 µg/ml combined with L-OHP). activity (Fig. 7D) . HT-29 cells were also treated with salidroside, and then drug-resistant genes and caspase-3 activity were also tested. Results of salidroside on HT-29 cells were similar to those of salidroside on HT-29/L-OHP cells (Fig. 8) .
Discussion
CRC is a common malignant digestive tract tumor in China, which is characterized by the dissatisfactory therapeutic efficacy and poor prognosis (21, 22) . Chemotherapy plays an important role in the treatment of CRC, which, however, frequently fails and results in recurrence and metastasis due to the drug resistance of CRC cells (23, 24) . L-OHP, a 3rd generation platinum-based anticancer drug, is the primary component in the first-line chemotherapy for CRC. The cytotoxic and anti-cancer effect of L-OHP is to inhibiting DNA synthesis in the cancer cells by creating crosslink within and between DNA chains (25, 26) . Although the effect of L-OHP is better than DDP, the resistance of CRC cells against L-OHP decreases the clinical outcomes (27, 28) . In this study, the cell activity of CRC cells was lower than L-OHP resistance CRC cells after L-OHP intervention, demonstrating the resistance of CRC cells to L-OHP (29) . Therefore, a combination of innovative drugs and L-OHP may improve the effectiveness of chemotherapy.
Rhodiolae, a traditional medicinal plant, is widely used in Far East and Russia (15, 16) for immunity improvement (30), anti-oxidation/cancer (31, 32) , cardiovascular protection (33), glycol-/lipid-metabolism enhancement and neuron protection (34, 35) . Salidroside is the active ingredient of Rhodiolae, which has obvious suppression on renal clear cell cancer, lung cancer and breast cancer (17) (18) (19) . Recent evidence has demonstrated that salidroside could inhibit the proliferation of CRC cells by regulating the JAK2/STAT3 signaling. However, whether Rhodiolae can relieve the resistance of CRCs against L-OHP remains unclear. In this study, we observed higher sensitivity of CRC cells to L-OHP after salidroside inter- Previous studies revealed the participations of agent pump protein, detoxification pathway and DNA repair in the L-OHP resistance (36) (37) (38) (39) . To explore the mechanism of salidroside on HT-29/L-OHP and HT-29 cells, we compared the expressions of MRP-1, P-gp, LOXL2, Survivin, Livin and Bcl-2 before and after salidroside intervention. MRP-1 and P-gp, located at the membrane of cancer cells, could pump chemotherapeutic drugs out via endoergic reaction (40, 41) . Recent study has demonstrated that LOXL2 can inhibit the diffusion of gemcitabine in the pancreatic ductal adenocarcinoma (PDAC) (42) . Survivin (43) , Livin (44) and Bcl-2 could enhance the anti-apoptosis of cancer cells, while in contrast Bax can promote apoptosis. Therefore, the ratio of Bcl-2/Bax in the dimer composed by the two proteins determines the apoptosis capacity of cancer cells (45, 46) . In this study, we observed declines of MRP-1, MDR1/P-gp, LOXL2, Survivin, Livin and Bcl-2, whereas increasing expression of Bax after salidroside intervention, suggesting salidroside can relieve the resistance of CRC cells to L-OHP by regulating these drug-resistant genes. Results of salidroside on HT-29 cells were similar to those of salidroside on HT-29/L-OHP cells. However, more studies are needed to explore the interaction between specific molecules, and in further study we'll investigate effects of salidroside on other CRC cell lines.
In conclusion, our study revealed that salidroside could decrease the activity and invasion capacity of HT-29/ L-OHP, and treatment of salidroside related to apoptosis of cancer cells by regulating the expressions of related genes, possibly due to inhibiting the expressions of MRP-1, MDR1/P-gp, LOXL2, Survivin, Livin and Bcl-2, whereas promoting the expression of Bax genes. Therefore, we suggest the combined application of salidroside in the L-OHP oriented chemotherapy in order to improve the clinical efficacy for CRC patients. However, further researches are needed to confirm this conclusion via in vivo experiments and large-scale clinical studies.
